After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved ... Seaport said the money would support a pipeline of improved neuropsychiatric drug ...

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics. Karuna co-founder Daphne ...

About Seaport Therapeutics Seaport Therapeutics is a ... All the therapeutic candidates in its pipeline of potentially first and best-in-class medicines are based on the Glyph platform, which ...

Seaport Therapeutics (“Seaport” or the “Company ... All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely ...

US clinical-stage biotherapeutics company, Seaport Therapeutics’ investigational allopregnanolone prodrug, SPT-300, has been well tolerated in a Phase I trial. The company has published data ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team ...

2024--(BUSINESS WIRE)--Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and ...

Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage ... All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is ...

including without limitation those related to Seaport’s development plans for its pipeline of therapeutics for the treatment of depression, anxiety and other neuropsychiatric disorders ...